473 related articles for article (PubMed ID: 20841516)
1. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
3. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
4. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
6. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
7. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
[TBL] [Abstract][Full Text] [Related]
8. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Patel KS; Lau JE; Zembillas AS; Gallagher EM
J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
[TBL] [Abstract][Full Text] [Related]
9. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
13. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
14. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Trifilio S; Gordon L; Singhal S; Tallman M; Evens A; Rashid K; Fishman M; Masino K; Pi J; Mehta J
Bone Marrow Transplant; 2006 Jun; 37(11):997-1001. PubMed ID: 16708061
[TBL] [Abstract][Full Text] [Related]
15. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
16. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
17. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
19. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Trifilio SM; Pi J; Zook J; Golf M; Coyle K; Greenberg D; Newman D; Koslosky M; Mehta J
Bone Marrow Transplant; 2011 Jun; 46(6):800-5. PubMed ID: 20818444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
